Evolus, Inc. (EOLS) Investor Relations Documents

Evolus, Inc. (EOLS) investor relations documents from the company's IR site: 2 presentations, 36 press releases; latest deck 2026-05-04. Read in-app with summaries. First-party data.

Download PDF file, (opens in new window): Evolus May 2026 investor presentation detailing the clinical performance and market strategy for its Evolysse® hyaluronic acid (HA) dermal filler line.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-05Press releasePress Release
2026-08-04Press releaseEvolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
2026-07-22Press releaseEvolus to Report Second Quarter Financial Results on August 5, 2026
2026-07-10Press releaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-08Press releaseDownload PDF, Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United
2026-06-04Press releaseEvolus to Participate in The Jefferies Global Healthcare Conference
2026-05-19Press releaseDownload PDF, Evolus to Participate in The Jefferies Global Healthcare Conference, May 19, 2026, (opens in new window)
2026-05-11Press releaseEvolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
2026-05-04Press releaseEvolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EB
2026-05-04PresentationDownload PDF file, (opens in new window)
2026-05-04Press releasePress Release of Q1 2026, PDF file, (opens in new window)
2026-04-14Press releaseEvolus to Report First Quarter Financial Results on May 4, 2026
2026-04-14Press releaseEvolus to Report First Quarter Financial Results on May 4, 2026
2026-04-14Press releaseEvolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
2026-03-31Press releaseDownload PDF, Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference, March 31, 2026, (opens in
2026-03-20Press releaseDownload PDF, Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), March 20, 2026, (opens in new windo
2026-03-11Press releaseEvolus to Participate in The Leerink Partners Global Healthcare Conference
2026-03-03Press releaseEvolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Grow
2026-03-03Press releaseEvolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Grow
2026-02-25Press releaseDownload PDF, Evolus to Participate in The Leerink Partners Global Healthcare Conference, February 25, 2026, (opens in n
2026-02-17Press releaseEvolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
2026-02-17Press releaseEvolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026
2026-02-13Press releaseDownload PDF, Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), February 13, 2026, (opens in new wi
2026-01-09Press releaseDownload PDF, Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue, January 9, 2026, (op
2026-01-02PresentationDownload PDF (opens in new window)
2025-11-05Quarterly reportView full release of Q3 2025 Earnings, (opens in new window)
2025-08-05Quarterly reportView full release of Q2 2025 Earnings, (opens in new window)
2025-03-04Press releaseQ4
2024-11-06Press releaseQ3
2024-07-31Press releaseQ2
2024-05-07Press releaseQ1
2024-03-07Press releaseQ4
2023-11-07Press releaseQ3
2023-08-02Press releaseQ2
2023-05-09Press releaseQ1
2023-03-08Press releaseQ4
2022-11-08Press releaseQ3
2022-08-02Press releaseQ2
2022-05-10Press releaseQ1
2022-03-03Press releaseQ4

EOLS overview · EOLS earnings · EOLS financials · EOLS KPIs · EOLS ownership · EOLS peers · EOLS filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.